Myelodysplastic Syndromes

Future Management of Myelodysplastic Syndromes

February 7th 2022, 2:20pm


Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

Interchangeability Between Oral and IV Agents in HR-MDS

February 7th 2022, 2:00pm


Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Oral Therapy for HR-MDS: Addressing Patient Adherence

January 31st 2022, 2:20pm


Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Practical Considerations for the Use of HMAs in Higher-Risk MDS

January 31st 2022, 2:00pm


Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Impact of an Oral HMA on the HR-MDS Treatment Landscape

January 31st 2022, 2:00pm


Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Higher-Risk MDS: When to Use HMA Therapy or Lenalidomide

January 24th 2022, 2:20pm


Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Goals of Therapy for Patients With Myelodysplastic Syndromes

January 24th 2022, 2:00pm


Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

Factors in Selecting Therapy for Myelodysplastic Syndromes

January 17th 2022, 2:20pm


A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Considering the Role of ESAs and Blood Transfusions in MDS Management

January 17th 2022, 2:00pm


Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

Gaps in the Diagnosis and Treatment of Myelodysplastic Syndromes

January 10th 2022, 2:20pm


Experts consider shortcomings in the identification and management of myelodysplastic syndromes.